Public Policy Sessions at Annual Symposium
AMIA's 2025 Annual Symposium takes place in Atlanta, GA, November 15-19. Two policy sessions are being offered this year.
W30: Moving Evidence to Policy - A Workshop of Best Practices to Use Evidence to Advocate for the Adoption of Policy
Sunday, Nov. 16 | 8:30 a.m. – 12:00 p.m. | M105
In a climate of open attacks on the integrity and necessity of rigorously generated evidence that is needed to inform and support important policy decisions, biomedical informatics scientists need skills and approaches of best practices on how to apply evidence to advocate for policy positions. The impact of evidence, generated through rigorously applied scientific methods, can result in evidence-based policy decisions. However, biomedical informatics scientists may not always recognize that the evidence that they generate can influence policymaking. This workshop will use examples of how evidence can be used in a variety of settings to inform policy decisions that impact the application and use of biomedical informatics.
S21: AMIA in Washington: A Federal Policy Year-in-Review at AMIA 2025
Monday, Nov. 17 | 8:00 – 9:15 a.m. | A701
Discover how AMIA is shaping the national health informatics agenda at AMIA 2025. Led by the Public Policy Committee, this session will unpack our 2025 priorities, principles, and flagship efforts, from Hill Day to ongoing advocacy initiatives, while tracing how our strategy evolved to meet the moment. We’ll also preview what’s ahead in 2026 and invite your questions and insights.
Plan now to join us in Atlanta! Learn more about Symposium.
Top News for Informatics
White House Office of Science and Technology Policy Request Information to Reform Artificial Intelligence
The White House Office of Science and Technology Policy (OSTP) issued a Request for Information (RFI) seeking public input on how existing federal laws and regulations may impede the development and adoption of artificial intelligence (AI). In response, AMIA urged regulatory reforms that promote responsible AI use in healthcare while safeguarding patients. AMIA’s comments highlight opportunities to reduce documentation and prior authorization burdens, establish transparency and labeling standards, and develop risk-based frameworks and interoperability standards, ensuring AI systems advance innovation, fairness, and equitable, high-quality care across the healthcare ecosystem.
FDA RFI: Measuring and Evaluating AI-Enabled Medical Device Performance in the Real World
The Food and Drug Administration (FDA) seeks feedback on a series of questions related to the current, practical approaches to measuring and evaluating the performance of AI-enabled medical devices in the real-world, including strategies for identifying and managing performance drift. The RFI is available here. Comments are due December 1.
ICYMI
Timeline of Government Shutdown and Its Impact on Health and Research
October 1 full federal government shutdown halted discretionary operations and disrupted federal research agencies. NIH paused grant support, OMB removed back pay guarantees, and the Trump Administration initiated layoffs across HHS and CDC, affecting over 4,000 workers before a federal judge intervened. Amid the turmoil, the Administration expanded its “University Compact,” linking grant access to policy alignment. The shutdown has intensified uncertainty across the scientific community, stalling key medical and public health research nationwide.
Review all of this Administration’s actions that has affected medical and public health research: Timeline-of-Administration-Actions-10.16-Update.pdf